
Inflation Reduction Act’s Impact on Pharma’s Future
Article Summary – The Inflation Reduction Act (IRA) is expected to change how Medicare negotiates drug prices, projecting savings of around $300 billion in Medicare drug costs over the next decade. However, this may cause a reduction in revenues for the biopharma industry, totaling about $75 billion due to strict





